Literature DB >> 11731410

Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

F Yagasaki1, D Wakao, Y Yokoyama, Y Uchida, I Murohashi, H Kayano, M Taniwaki, A Matsuda, M Bessho.   

Abstract

Fusions of the ETV6/TEL gene to receptor or protein tyrosine kinases (TKs), such as PDGFRbeta, JAK2, ABL, ABL2, TRKC, and Syk, have been reported in various hematological malignancies. Expression of the resultant chimeric proteins is believed to lead to constitutive TK activity through activation by the helix-loop-helix (HLH) domain of ETV6. We identified a novel ETV6 partner gene, fibroblast growth factor receptor 3 (FGFR3), in a patient with peripheral T-cell lymphoma (PTCL) with a t(4;12)(p16;p13) translocation. The ETV6-FGFR3 transcript showed a fusion of exon 5 of ETV6 to exon 10 of FGFR3, resulting in an open reading frame for a chimeric protein consisting of the HLH domain of ETV6 and the TK domains of FGFR3. This is the first report of ETV6 and FGFR3 involvement in PTCL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11731410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

Review 2.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.

Authors:  Timothy Carll; Anand Patel; Benjamin Derman; Elizabeth Hyjek; Angela Lager; Pankhuri Wanjari; Jeremy Segal; Olatoyosi Odenike; Shiraz Fidai; Daniel Arber
Journal:  Blood Adv       Date:  2020-10-13

4.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

5.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

6.  Dependence receptor TrkC is a putative colon cancer tumor suppressor.

Authors:  Anne-Laure Genevois; Gabriel Ichim; Marie-May Coissieux; Marie-Pierre Lambert; Fabrice Lavial; David Goldschneider; Loraine Jarrosson-Wuilleme; Florian Lepinasse; Géraldine Gouysse; Zdenko Herceg; Jean-Yves Scoazec; Servane Tauszig-Delamasure; Patrick Mehlen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

Review 7.  Translocations in epithelial cancers.

Authors:  J Chad Brenner; Arul M Chinnaiyan
Journal:  Biochim Biophys Acta       Date:  2009-05-04

Review 8.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

9.  Identification and characterization of renal cell carcinoma gene markers.

Authors:  Gul S Dalgin; Dustin T Holloway; Louis S Liou; Charles DeLisi
Journal:  Cancer Inform       Date:  2007-02-09

10.  Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells.

Authors:  M Hirotsu; T Setoguchi; Y Matsunoshita; H Sasaki; H Nagao; H Gao; K Sugimura; S Komiya
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.